Abstract 2121P
Background
Recently, the development of anticancer drug administration methods and advances in supportive care for side effects have made it possible to safely perform chemotherapy through outpatient visits. Outpatient chemotherapy is important for maintaining the patient's quality of life (QOL). Side effects of chemotherapy include anorexia, nausea, dysgeusia, and oral mucosal disorders, which affect diet, and weight loss affecting the effectiveness and prognosis. In particular, patients with gastrointestinal cancer are considered to have a high nutritional risk status. We assessed the nutritional status of patients with gastrointestinal cancer during outpatient chemotherapy and found an association with adverse events symptoms.
Methods
The Tohoku University School of Medicine IRB approved this study (2018-1-176); patients provided written informed consent. Patients undergoing outpatient chemotherapy were enrolled, nutritional status, self-assessment of adverse events and depression by The Depression Scale Epidemiological Research Center (CES-D) were assessed. Responses were analyzed by Chi-squared test, ANOVA, Spearman's correlation coefficient, and multiple regression analysis. p<0.05 was considered significant. All statistical analyses were performed using SPSS (ver. 21).
Results
Valid responses were obtained from 120 patients with gastrointestinal cancers including pancreatic, colorectal, gastric, and esophageal cancers. The mean age was 65.2 (±9.6) years. Side effects of chemotherapy were fatigue in 99 (83.9%), neuropathy in 88 (73.3%), and dysgeusia in 85 (70.8%). Subjects were classified into 70 normal persons, 32 malnourished, 6 pre-cachexia, and 12 cachexia according to the nutrition assessment classification by Glasgow prognostic score (GPS). Although GPS classification did not show a significant relationship with the basic attributes, there was a significant relationship between anorexia (r=0.26, p=0.004), taste change (r=0.26, p=0.005), dry mouth (r=0.18, p=0.049), and edema (r=0.22, p=0.018).
Conclusions
Adverse events during chemotherapy including anorexia, dysgeusia, dry mouth and edema would have negative impact on nutritional status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
JSPS KAKENHI Grant Number JP 16K07140.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06